CWIR yields 20000000.00% · ABBV yields 3.06%● Live data
📍 CWIR pulled ahead of the other in Year 1
Combined, CWIR + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of CWIR + ABBV for your $10,000?
Central Wireless, Inc., a development stage company, operates as a wireless communications infrastructure company. It primarily engages in the design, engineering, development, and construction of towers for the transmission of broadband, cellular, and other wireless communications signals. These towers include the monopole, the guy tower, stealth tower designs, and self-support towers, and broadcast telecommunications signals for personal communications services, cellular, wireless data, paging, and broadcast technologies. The company also provides related services, including site acquisition, zoning, and antennae and line installation. It also offers various consulting services, including lease negotiation and assistance in regulatory matters. The company's customers primarily include broadband and other wireless telecommunications carriers, and individuals or businesses that desire to lease or own telecommunications towers. It principally operates in the greater Sarasota, Florida region; Oklahoma; and Minnesota in the United States. Central Wireless, Inc. is based in Las Vegas, Nevada.
Full CWIR Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.